This item is in: Biomedicine > Intellectual property, regulation
The impact of regulation on drug developmentG H Hennings, hgh regulatory sciences, Germany
Woodhead Publishing Series in Biomedicine No. 36
- covers the impact of globally harmonised regulatory requirements on the different sectors of drug development regarding quality, safety and efficacy and their timing from discovery to the post-authorisation phase
- examines the crucial role of scientific (and regulatory) advice and practical steps on how to obtain it effectively
- establishes flexible global regulatory planning and strategies
- the role and responsibilities of regulatory science management in the drug development process are discussed
The impact of regulation on drug development provides the reader with a basic understanding of the evolution of global regulatory standards relevant to the research and development process of medicinal products and the role regulatory science plays, i.e. the science of developing new tools, standards and approaches to assess the safety, efficacy, quality and performance of regulated products.
In light of the high-growth expectations of international investors, the increasing costs of research and development, and the challenges to patent protection, the pharmaceutical industry is in urgent need of substantial improvements in research and development productivity.
The global framework of national legislations, (partly) harmonised guidelines and their evolution provides challenges and opportunities to an efficient management of the R&D process, which should be targeted to receive timely marketing authorisations and viable pricing and reimbursement decisions.
Standard R&D strategies established originally for small molecules have to be intensively reviewed against this regulatory frame. This is particularly true if development projects are derived from biotechnological processes such as recombinant DNA technology, controlled expression of genes coding for biologically active proteins in prokaryotes and eukaryotes including transformed mammalian cells, hybridoma and monoclonal antibody methods or advanced therapy medicinal products such as gene or somatic cell therapy or tissue engineered products.
Scientific (and regulatory) advice provided by health authorities should be considered as a potential value-increasing instrument in order to focus and streamline the R&D process.
This book provides practical guidance on how to obtain such advice efficiently and how it is incorporated in global regulatory planning and strategies.
ISBN 1 907568 70 0
ISBN-13: 978 1 907568 70 1
December 2014
200 pages 234 x 156mm hardback
Approx. £120.00 / US$205.00 / €145.00
Not yet published
 | An e-book version of this title will be available from
Woodhead Publishing Online. To view the current titles available visit Woodhead Publishing Online
|
About the author
Dr Guenter Hennings is the Director of hgh regulatory sciences, a German consulting firm providing regulatory assistance for the development of medicinal products. He has over 30 years senior management experience in drug research and development in top-tier global pharmaceutical companies - including the successful global marketing authorisation applications for more than ten new active substances, resolution of drug safety and pharmacovigilance issues and EU referral procedures.
In addition to his activities as consultant Dr Hennings currently serves as a visiting scientist at the department of Regulatory Affairs, University of Bonn, Germany. He is widely published, with a number of articles in both biochemical pharmacology and regulatory sciences.
Titles which may also be of interest:
Biobanks
Contract research and manufacturing services (CRAMS) in India
Quality assurance
Contents
Developing effective medicines - a contribution to public health; Evolution and maintenance of global regulatory standards; Current regulatory issues of research and development pipelines; The value chain from discovery to post-authorisation research; Health authorities provide scientific (and regulatory) advice; Strategic regulatory plans and planning.